The National Institute for Health and Clinical Excellence (NICE) has been ordered to reconsider and reissue guidance on the use of strontium ranelate (Protelos®) by the Court of Appeal.
The manufacturer of strontium ranelate successfully argued that NICE failed to provide sufficient reasoning behind the decision to reject post-hoc evidence relating to the efficacy of the drug in reducing hip fractures. NICE must now reconsider the evidence and issue fresh advice within 3 months.
NICE has advised that the recommendations in the osteoporosis - primary prevention and the osteoporosis - secondary prevention guidelines that relate to strontium will be withdrawn pending this review. All of the other recommendations remain in place. Local arrangements will need to made in order to identify when strontium ranelate can be prescribed until the new guidance is published.
Action: Clinicians should be aware of this decision. It may be prudent to continue to follow the previous guidance while the review in finalised.
|« ACCORD subgroup analyses||Election delays guidance »|